unknown by Dimitrios-Petrou Bogdanos et al.
BioMed CentralJournal of Autoimmune Diseases
ssOpen AcceResearch
Antibodies to soluble liver antigen and α-enolase in patients with 
autoimmune hepatitis
Dimitrios-Petrou Bogdanos1, Daniele Gilbert2, Ilaria Bianchi1, 
Simona Leoni1, Ragai R Mitry1, Yun Ma1, Giorgina Mieli-Vergani1 and 
Diego Vergani*1
Address: 1Institute of Liver Studies, King's College Hospital, Denmark Hill, London SE5 9RS, UK and 2Faculté de Médecine et Pharmacie, U519 
INSERM, University of Rouen, Rouen, France
Email: Dimitrios-Petrou Bogdanos - dimitrios.bogdanos@kcl.ac.uk; Daniele Gilbert - Daniele.Gilbert@univ-rouen.fr; 
Ilaria Bianchi - ilaria.bianchi@libero.it; Simona Leoni - leonisimona@yahoo.it; Ragai R Mitry - ragai.mitry@kcl.ac.uk; 
Yun Ma - yun.ma@kcl.ac.uk; Giorgina Mieli-Vergani - giorgina.vergani@kcl.ac.uk; Diego Vergani* - diego.vergani@kcl.ac.uk
* Corresponding author    
Abstract
Background: Antibodies to a cytosolic soluble liver antigen (SLA) are specifically detected in patients with
autoimmune hepatitis (AIH). The target of anti-SLA has been identified as a ~50 kDa UGA serine tRNA-associated
protein complex (tRNP(Ser)Sec), through the screening of cDNA libraries. A recent report questioned the identity
of tRNP(Ser)Sec as the real SLA antigen. The latter study identified α-enolase as a major anti-SLA target, through
proteomic analysis.
Methods: In an attempt to explain the observed discrepancy we have investigated reactivity of SLA positive sera
against α-enolase and tRNP(Ser)Sec using rat and primate liver homogenate and the recombinant antigens. Thirty-
three serum samples, 11 from SLA-positive patients and 22 from SLA negative controls were investigated. SLA
antibodies were detected by an inhibition ELISA and confirmed by immunoblot using human liver homogenate.
Autoantibody reactivity was further evaluated using preparations of primate and rat liver homogenates. Anti-α-
enolase antibody reactivity has been tested by immunoblot using recombinant α-enolase. An affinity purified goat
polyclonal anti-α-enolase IgG antibody was used as reference serum sample. Anti-tRNP(Ser)Sec antibody reactivity
was detected by ELISA or dot blot using recombinant tRNP(Ser)Sec antigen.
Results and Discussion: The affinity purified IgG antibody directed to human α-enolase gave a band of
approximately 48 kDa in both human and rat liver homogenates. A high titre anti-tRNP(Ser)Sec antibody serum gave
a single band of ~50 kDa in both liver preparations. All but one anti-SLA antibody positive sera reacted with a
~50 kDa but none immunofixed a 48 kDa band. All anti-SLA antibody positive sera reacted strongly with the
recombinant full length tRNP(Ser)Sec protein. None of the anti-SLA negative sera reacted with tRNP(Ser)Sec. Anti-
SLA positive, and anti-SLA negative sera reacted equally against recombinant α-enolase by immunoblot. Pre-
incubation of anti-SLA positive sera with tRNP(Ser)Sec completely abolished the 50 kDa band. The findings of the
present study indicate that α-enolase and tRNP(Ser)Sec are both expressed in primate and rat liver and have a
respective MW of 48 and 50 kDa. They also show that anti-tRNP(Ser)Sec – but not anti-α-enolase – correlates with
anti-SLA antibody reactivity.
Conclusion: Our findings indicate that tRNP(Ser)Sec is the most likely target of anti-SLA.
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Antibodies to a cytosolic soluble liver antigen (SLA),
detected originally by an inhibition ELISA using cytosolic
liver fractions in a sub-group of patients with autoim-
mune hepatitis (AIH) negative for other autoantibodies,
have recently been also reported in adult patients with
anti-nuclear and/or smooth muscle antibody (ANA/SMA)
positive type 1 AIH and in seronegative patients with a
form of cryptogenic hepatitis resembling type 1 AIH [1-6].
In pediatric patients, anti-SLA has been described not only
in type 1 AIH but also in anti-liver kidney microsomal-1
antibody positive type 2 AIH and autoimmune sclerosing
cholangitis [7-10]. Anti-SLA is specific for these autoim-
mune liver diseases, where it is associated with a more
severe course and is virtually absent in non-hepatic
autoimmune disorders [1-9]. The target of anti-SLA has
been identified by several groups as a ~50 kDa UGA serine
tRNA-associated protein complex (tRNP(Ser)Sec), through
the screening of cDNA libraries [2-4,7]. Anti-tRNP(Ser)Sec
antibodies have been detected in up to 90% of serum
samples positive for SLA by the original inhibition ELISA
[1-8].
Using anti-SLA positive sera against rat liver cytosolic frac-
tion in one and two-dimensional immunoblotting analy-
ses and through peptide mass fingerprint analysis,
following MALDI-TOF mass spectrometry, Ballot et al.
[11] identified four isoforms of α-enolase, – a cytosolic
antigen of 48–50 kDa –, as the major target of anti-SLA
positive sera. These findings challenge the notion that
tRNP(Ser)Sec is the sole target of anti-SLA antibodies [2-8].
Critically, no absorption studies were performed with
purified α-enolase to confirm this proposal [11]. Moreo-
ver, α-enolase has been described as an antigen in several
autoimmune disorders totally unrelated to autoimmune
hepatitis [12-18].
Using recombinant tRNP(Ser)Sec antigen as competitor in
inhibition experiments it has been found removal of the
50 kDa band immunofixed by SLA positive sera from
immunoblots of primate liver homogenate [19]. Though
this finding indicates tRNP(Ser)Sec as a major component of
SLA, a view apparently shared by Ballot et al, several ques-
tions still remain unanswered:
1. Are there any differences in α-enolase expression
between rat – used by Ballot et al [11] – and primate liver
homogenate – used by our study [19] – that could explain
the discrepancy between these studies?
2. Is it true that failure of proteomic analysis to detect
tRNP(Ser)Sec is due to its presence in trace amounts in the
supernatant of liver homogenate [11]?
3. What is the reactivity of SLA positive and negative sera
against recombinant α-enolase?
4. How do we explain the apparent paradox of SLA being
identified as α-enolase by proteomic analysis and as
tRNP(Ser)Sec by the screening of cDNA libraries? Do α-eno-
lase and tRNP(Ser)Sec cross-react?
In the present study, we have investigated reactivity of SLA
positive sera against α-enolase and tRNP(Ser)Sec using rat




Thirty-three serum samples, 11 from SLA-positive patients
and 22 from SLA negative controls were investigated. SLA-
positive patients included 8 paediatric patients with AIH1
[7 female, median age 12, range 5–17 years, all ANA pos-
itive, median immunofluorescence (IFL) titre: 1/320,
range 1/80–1/1280] and 3 adults with AIH/PBC overlap
syndrome, (2 female, median age 56, range 47–65), all
but one AMA positive (1/5120), and ANA positive
(median tire 1/320, range 1/80–1/640). Eleven case-
matched SLA negative patients were tested as pathological
controls including 8 with AIH1 and 3 with AIH/PBC over-
lap syndrome. Eleven demographically matched healthy
subjects including 8 children (7 female, median age 11,
range 6–16) and 3 adults (2 female, median age 53, range
42–63) negative for SLA were also tested as controls.
Antibody Detection
All sera have been tested for conventional antibodies by
indirect IFL using rodent liver, kidney, stomach tissues.
SLA antibodies were detected by a modified inhibition
ELISA [1] and confirmed by immunoblot using human
liver homogenate [20]. Autoantibody reactivity was fur-
ther evaluated using preparations of primate (Euroim-
mun, Lubeck, Germany) and rat (AID Autoimmun
Diagnostika GmbH, Strassberg, Germany) liver homoge-
nates, according to manufacturers' instructions. Anti-α-
enolase antibody reactivity has been tested by immunob-
lot using recombinant α-enolase, as described previously
[17]. Briefly, the complete complementary DNA (cDNA)
encoding human α-enolase was isolated from a cDNA
expression library derived from synoviocytes obtained
from a patient with rheumatoid arthritis (Stratagene, La
Jolla, CA) and immunoscreened with goat anti-enolase
antibodies. This cDNA was subcloned in frame in the
pSPUTK in vitro translation vector (Stratagene) using the
Apa I and Bam HI restriction sites. The translation product
was synthesized as a separated biotinylated polypeptide,
purified by SoftLink Soft Release Avidin Resin (Promega,
Madison, WI), migrated in SDS-PAGE, according to thePage 2 of 6
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cellulose membrane [17]. The filters were then incubated
with goat anti-enolase antibodies (see below), a mono-
specific anti-α-enolase antibody positive serum from a
patient with rheumatoid arthritis or with individual
serum samples, in Tris buffered saline, 0.05% Tween 20,
5% dry milk for 2 hours. After washing, the filters were
incubated for 1 hour with 1:15,000-diluted peroxidase-
conjugated goat anti-human IgG (Sigma-Aldrich) in
0.05% TBST-milk. The filters were washed and revealed by
a chemiluminescence reaction (Supersignal; Pierce, Rock-
ford, IL) [17].
An affinity purified goat polyclonal anti-α-enolase IgG
antibody raised against a peptide mapping near the car-
boxyl-terminus of human α-enolase, which is common to
α, β, and γ isoforms of mouse, rat and human enolase
(200 µg/ml; Santa Cruz Biotechnology, Santa Cruz, Cali-
fornia, USA) was used as reference serum sample at a dilu-
tion of 1:100, according to the manufacturer's
instructions.
Anti-tRNP(Ser)Sec antibody reactivity was detected by ELISA
or dot blot using recombinant tRNP(Ser)Sec antigen
(Euroimmun). A high-titre anti-tRNP(Ser)Sec antibody pos-
itive serum was used as a positive control.
Immunoblot patterns produced by anti-α-enolases and anti-tRNP(Ser)Sec antibodies on electrophoretically separated primate and rat liver homogenates and dot blot results with recombinant tRNP(Ser)SecFigure 1
Immunoblot patterns produced by anti-α-enolases and anti-tRNP(Ser)Sec antibodies on electrophoretically separated primate 
and rat liver homogenates and dot blot results with recombinant tRNP(Ser)Sec. In both rat and primate liver preparations, a band 
of ~48 kDa is immunofixed by a polyclonal goat IgG anti-α-enolase specific antibody; a band of ~50 kDa is immunofixed by a 
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Immunoblot patterns produced on rat liver homogenate by (lane 1) a polyclonal goat IgG anti-α-enolase specific antibody; 
(lanes 2–5) four representative anti-soluble liver antigen (SLA) positive sera; (lane 6) a reference serum containing high-titre 
anti-tRNP(Ser)Sec antibody.
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To investigate whether the 50 kDa band immunofixed by
anti-SLA is tRNP(Ser)Sec, inhibition experiments were per-
formed using 3 anti-SLA positive serum samples, diluted
at 1/1000, and pre-incubated with solid phase recom-
binant tRNP(Ser)Sec (Euroimmun, UK), as previously
described [19].
Results and Discussion
The affinity purified IgG antibody directed to human α-
enolase gave a band of approximately 48 kDa in both
human and rat liver homogenates as shown in Figure 1. A
high titre anti-tRNP(Ser)Sec antibody serum gave a single
band of ~50 kDa in both liver preparations (Figure 1). All
but one anti-SLA antibody positive sera reacted with a ~50
kDa band similar to that obtained by the high titre anti-
tRNP(Ser)Sec antibody serum in rat liver preparations (Fig-
ure 2) but none immunofixed a 48 kDa band. All anti-SLA
antibody positive sera reacted strongly with the recom-
binant full length tRNP(Ser)Sec protein both in ELISA
(mean titre 87 ± 23 RU/ml, cut off: 20 RU/ml) and dot
blot. None of the anti-SLA negative sera reacted with
tRNP(Ser)Sec. Anti-SLA positive, and anti-SLA negative sera
reacted equally against recombinant α-enolase by immu-
noblot with 5/9 cases in each group giving a strong band
(Figure 3).
Pre-incubation of anti-SLA positive sera with tRNP(Ser)Sec
completely abolished the 50 kDa band immunofixed in
either rat or human liver preparation. In contrast, a paral-
lel experiment where the anti-α-enolase antiserum was
pre-incubated with recombinant tRNP(Ser)Sec left unaltered
the reactivity to the 48 kDa band.
The findings of the present study indicate that α-enolase
and tRNP(Ser)Sec are both expressed in primate and rat liver
and have a respective MW of 48 and 50 kDa. They also
show that anti-tRNP(Ser)Sec – but not anti-α-enolase – cor-
relates with anti-SLA antibody reactivity suggesting that
the target of anti-SLA antibody is tRNP(Ser)Sec and not α-
enolase [1-9,19].
However, Ballot et al [11] state that α-enolase is a major
SLA antigen since rat α-enolases have MW of 47.4 to 47.5
and Pi values of 5.8 to 6.2. These characteristics do not
match the MW (48.8) and Pi (8.6) of tRNP(Ser)Sec. Ballot et
al [11], however, show a Coomassie stained 2D-gel over
the Pi range 6 to 11 and an immunoblot of this gel with
several bands of a Pi above 8, but have not investigated
these bands by MALDI-TOF analysis being therefore una-
ble to rule out their possible relation to tRNP(Ser)Sec.
Conclusion
All the above observations indicate that tRNP(Ser)Sec is the
most likely target of anti-SLA.
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Immunoblot patterns obtained using 9 SLA positive and 9 SLA negative serum samples against recombinant α-enolaseFigure 3
Immunoblot patterns obtained using 9 SLA positive and 9 SLA negative serum samples against recombinant α-enolase. A poly-
clonal goat IgG anti-α-enolase specific antibody has been used as a reference positive serum. Ab, antibody; ag, antigen
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